Search company, investor...


Founded Year



Convertible Note - II | Dead

Total Raised


Last Raised


About Circadian

Manufacturer of portable ambulatory ECG units, pulmonary test units, automatic blood chemistry analyzers. New product focus is on a laser-based surgical instrument for use in the doctor's office. The company was publicly traded OTC until taken private by the current investors. In early May 1993, Circadian announced their intent to acquire Airways for stock worth up to $2MM.

Headquarters Location

3942 North First Street

San Jose, California, 95134,

United States


Missing: Circadian's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Circadian's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Circadian

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Circadian is included in 1 Expert Collection, including Health Monitoring & Diagnostics.


Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

Circadian Patents

Circadian has filed 2 patents.

The 3 most popular patent topics include:

  • Acetylcholinesterase inhibitors
  • Agronomy
  • Chronobiologists
patents chart

Application Date

Grant Date


Related Topics



Food additives, Plant physiology, Acetylcholinesterase inhibitors, Insecticides, Agronomy


Application Date


Grant Date


Related Topics

Food additives, Plant physiology, Acetylcholinesterase inhibitors, Insecticides, Agronomy



Latest Circadian News

Circadian Technologies : CEO Terms of Employment

Apr 29, 2014

CIRCADIAN APPOINTS CEO AND MANAGING DIRECTOR - Notice of Employment Terms The Board of Directors of Circadian Technologies Limited (ASX:CIR) announced the appointment of Dr Megan Baldwin to the position of Chief Executive Officer and Managing Director, effective February 24 2014. Dr Baldwin brings over 18 years of experience focussing on angiogenesis and therapeutic strategies for cancer and ophthalmic indications. Dr Baldwin joined Circadian in 2008 and since then has held various positions, including Head of Preclinical R&D and Chief Executive Officer of Opthea Pty Ltd, the 100% owned subsidiary of Circadian, developing OPT-302 (formerly VGX-300) for the treatment of wet age-related macular degeneration. As Opthea CEO, Dr Baldwin led the capital management, investor engagement and advancement of Opthea's program for eye disease. Prior to that, Dr. Baldwin held research and commercial roles at Roche (formerly Genentech) in San Francisco. Dr. Baldwin completed her PhD in medicine at the Ludwig Institute for Cancer Research affiliated with the University of Melbourne. In accordance with ASX listing rule 3.16.4, the material terms of Dr Baldwin's employment as CEO of Circadian Technologies are provided below. Appointment Dr. Baldwin's employment as CEO and Managing Director of Circadian Technologies commenced on February 24 2014. Dr Baldwin's employment is ongoing, subject to 3 months notice of termination by either party. The Company can pay out the notice period. Base Remuneration $300,000 per annum, exclusive of statutory superannuation contributions. The base salary may be reviewed by the Chairman of Employer Board or her nominee. Short-Term Performance Incentive Dr Baldwin is eligible to receive an annual bonus of up to 50% of the base salary if agreed Key Performance Indicator/s are achieved. Long-Term Performance An employee share option plan (ESOP) or equivalent employee equity incentive plan will be implemented, the terms of which will be subject to shareholder approval. Subject to shareholder approval, Dr Baldwin will be offered the opportunity to participate in the ESOP. Suite 0403 Level 4 650 Chapel Street South Yarra Victoria 3141 Australia ABN 32 006 340 567 Media EnquiriesDavid Symons (02) 8306 4244 About Circadian Technologies Limited Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for 'back of the eye' disease such as wet age-related macular degeneration (wet AMD). Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3. Suite 0403 Level 4 650 Chapel Street South Yarra Victoria 3141 Australia ABN 32 006 340 567 distributed by

Circadian Frequently Asked Questions (FAQ)

  • When was Circadian founded?

    Circadian was founded in 1979.

  • Where is Circadian's headquarters?

    Circadian's headquarters is located at 3942 North First Street, San Jose.

  • What is Circadian's latest funding round?

    Circadian's latest funding round is Convertible Note - II.

  • How much did Circadian raise?

    Circadian raised a total of $8.45M.

  • Who are the investors of Circadian?

    Investors of Circadian include Technology Funding, Highland Capital Partners and Bryan and Edwards.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.